Top

Journal of Diabetes & Metabolic Disorders

Published in:

01-06-2021 | Glimepiride | Research article

Nephroprotective effect of Vanillic acid in STZ-induced diabetic rats

Authors: Savita Kumari, Anjoo Kamboj, Manish Wanjari, Anil Kumar Sharma

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2021

Abstract

Purpose

To investigate the protective effect of vanillic acid (VA) in streptozotocin (STZ)-induced diabetic nephropathy (DN) in rats.

Methods

Experimental diabetes mellitus in rats was induced by intraperitoneally administration of single dose of STZ (55 mg/kg). The animals were divided into 5 groups viz., normal control, diabetic control, glimepiride (0.5 mg/kg, orally) and VA treatment (50 and 100 mg/kg, orally) groups. The treatment was started after the confirmation of hyperglycemia (> 250 mg/dl) and continued for 6 weeks. Serum glucose level, and body weight were measured weekly. At the end of study, HbA1c in whole blood, insulin, lipid profile, urea, creatinine and albumin in serum. Creatinine and albumin were measured in urine along with creatinine clearance. In addition, kidney weight and histopathology were assessed.

Results

Treatment with VA markedly attenuated STZ-induced body weight loss and hyperglycemia, along with improved lipid profile and HbA1c, without significant alteration of serum insulin levels. It also decreased urea, creatinine and increased albumin in serum. Moreover, VA, significantly reduced urine volume, urinary albumin along with marked improvement in creatinine clearance. Further, the VA treatment significantly reverse the raised levels of oxidative stress markers, pro-inflammatory and fibrotic markers viz. TNF-α, IL-1β, IL-6, TGF-β1 and NFκB activity in kidney tissue. These effects are associated with amelioration of histopathological alterations compared to diabetic control rats. While glimepiride produced similar antihyperglycemic effect but the effect on albuminuria, oxidative stress markers and cytokine levels were less significant as compared to VA (100 mg/kg).

Conclusions

In conclusion, VA exhibited nephroprotective effect through amelioration of kidney dysfunction and damage in diabetic rats. The observed nephroprotective effect of VA may be ascribed to inhibition of hyperglycemia induced oxido-inflammatory stress and necroptosis of renal tissue possibly due to its antihyperglycemic, antioxidant and anti-inflammatory actions.

International Diabetes Federation. IDF. Diabetes Atlas. 9th ed. 2019. http://www.idf.org/diabetesatlas.

Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93:137–88.PubMed

Donate-Correa J, Luis-Rodriguez D, Martin-Nunez E, Tagua VG, Hernandez-Carballo C, Ferri C. Inflammatory targets in diabetic nephropathy. J Clin Med. 2020;9:458. https://doi.org/10.3390/jcm9020458.CrossRefPubMedCentral

Varghese RT, Jialal I. Diabetic Nephropathy. :Treasure Island: StatPearls Publishing LLC. 2020, https://www.ncbi.nlm.nih.gov/books/NBK534200/.

Zhu L, Han J, Yuan R, Xue L, Pang W. Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway. Biol Res. 2018;51:9. https://doi.org/10.1186/s40659-018-0157-8.CrossRefPubMedPubMedCentral

Toth-Manikowski S, Mohamed GA. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res. 2015. https://doi.org/10.1155/2015/697010.CrossRefPubMedPubMedCentral

Powers AC. Diabetes mellitus-mechanisms of complications. In: Kasper DL, Braunwald E, Anthony S, Stephen L, Dan L, Larry J, editors. Text Book of Harrison’s Principles of Internal Medicine. 16th ed. Vol. II. New York: McGraw-Hill Medical Publishing Division; 2020. p. 2164.

Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabeticnephropathy. Diabetes. 1983;32:64–78.PubMed

Ilyas Z, Chaiban JT, Krikorian A. Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy. Rev EndocrMetabDisord. 2017;18:21–8.

10.

Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19:433–42.PubMed

11.

Malik S, Suchal K, Khan SI, Bhatia J, Kishore K, Dinda AK. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways. Am J Physiol Renal Physio. 2017;313:414–22.

12.

Foggensteiner L, Mulroy S, Firth J. Management of diabetic nephropathy. J R Soc Med. 2001;94:210–17.PubMedPubMedCentral

13.

Tabatabaei-Malazy O, Larijani B, Abdollahi M. Targeting metabolic disorders by natural products. J Diabetes Metab Disord. 2015;14:57. https://doi.org/10.1186/s40200-015-0184-8.CrossRefPubMedPubMedCentral

14.

Aryaeian N, Sedehi SK, Arablou T. Polyphenols and their effects on diabetes management: A review. Med J Islam Repub Iran. 2017;31:134. https://doi.org/10.14196/mjiri.31.134.CrossRefPubMedPubMedCentral

15.

Almeida IV, Cavalcante FM, Vicentini VE. Different responses of vanillic acid, a phenolic compound, in HTC cells: cytotoxicity, antiproliferative activity, and protection from DNA-induced damage. Genet Mol Res. 2016;15:4. https://doi.org/10.4238/gmr15049388.CrossRef

16.

Itoh A, Isoda K, Kondoh M, Kawase M, Watari A, Kobayashi M, et al. Effect of syringic acid and vanillic acid on CCl4 induced liver injury. Biol Pharm Bull. 2010;33:983–7.PubMed

17.

Bernal-Mercado AT, Gutierrez-Pacheco MM, Encinas-Basurto D, Mata-Haro V, Lopez-Zavala AA, Islas-Osuna MA, et al. Synergistic mode of action of Catechin, Vanillic and Protocatechuic acids to inhibit the adhesion of uropathogenic Escherichia Coli on silicone surfaces. J Appl Microbiol. 2020;128:387–400.PubMed

18.

Kumar S, Prahalathan P, Raja B. Antihypertensive and antioxidant potential of vanillic acid, a phenolic compound in L-NAME-induced hypertensive rats: a dose dependence study. Redox Rep. 2011;16:208–15.PubMed

19.

Ji G, Sun R, Hu H, Xu F, Yu X, Veeraraghavan VP, et al. Vannilic acid ameliorates hyperglycemia-induced oxidative stress and inflammation in streptozotocin-induced diabetic rats. J King Saud Univ – Sci. 2020. Availabe from: https://doi.org/10.1016/j.jksus.2020.04.010.

20.

Chang WC, Wu JS, Chen CW, Kuo PL, Chien HM, Wang YT, et al. Protective effect of vanillic acid against hyperinsulinemia, hyperglycemia and hyperlipidemia via alleviating hepatic insulin resistance and inflammation in High-Fat Diet (HFD)-Fed Rats. Nutrients. 2015;7:9946–59.PubMedPubMedCentral

21.

Vinothiya K, Ashokkumar N. Modulatory effect of vanillic acid on antioxidant status in high fat diet-induced changes in diabetic hypertensive rats. Biomed Pharmacother. 2017;87:640–52.PubMed

22.

Alim Z, Kilinç N, Şengül B, Beydemir S. Inhibition behaviours of some phenolic acids on rat kidney aldose reductase enzyme: an in vitro study. J Enzyme Inhib Med Chem. 2017;32:277–84.PubMedPubMedCentral

23.

Sindhu G, Nishanthi E, Sharmila R. Nephroprotective effect of vanillic acid against cisplatin induced nephrotoxicity in wistar rats: a biochemical and molecular study. Environ Toxicol Pharmacol. 2015;39:392–404.PubMed

24.

Kim M, Kim S, Kim D, Jeon Y, Park SJ, Lee HS, et al. Vanillic acid inhibits inflammatory mediators by suppressing NF-κB in lipopolysaccharide-stimulated mouse peritoneal macrophages. Immunopharmacol Immunotoxicol. 2011;33:525–32.PubMed

25.

Dubey VK, Patil CR, Kamble SM, Tidke PS, Patil KR, Maniya PJ, et al. Oleanolic acid prevents progression of streptozotocin induced diabetic nephropathy and protects renal microstructures in Sprague Dawley rats. J Pharmacol Pharmacother. 2013;4:47–52.PubMedPubMedCentral

26.

Tripathi AS, Mazumder PM, Chandewar AV. Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in STZ-induced diabetic rats. J Basic Clin Physiol Pharmacol. 2016;27:57–62.PubMed

27.

Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother. 2010;1:87–93.PubMedPubMedCentral

28.

Eren Z, Gunal MY, Bakir EA, Coban J, Çağlayan B, Ekimci N, et al. Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats. Kidney Blood Press Res. 2014;39:581–90.PubMed

29.

Mestry SN, Dhodi JB, Kumbhar SB, Juvekar AR. Attenuation of diabetic nephropathy in streptozotocin-induced diabetic rats by Punica granatum Linn. leaves extract. J Tradit Complement Med. 2016;7:273–80.PubMedPubMedCentral

30.

Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–8.PubMed

31.

Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972;247:3170–5.PubMed

32.

Sinha AK. Colorimetric assay of catalase. Anal Biochem. 1972;47:389–94.PubMed

33.

Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82:70–7.PubMed

34.

Pelley JW, Garner CW, Little GH. A simple rapid biuret method for the estimation of protein in samples containing thiols. Anal Biochem. 1978;86:341–3.PubMed

35.

Cheng D, Liang B, Li Y. Antihyperglycemic effect of Ginkgo biloba extract in streptozotocin-induced diabetes in rats. Biomed Res Int. 2013. https://doi.org/10.1155/2013/162724.CrossRefPubMedPubMedCentral

36.

Papadopoulou-Marketou N, Kanaka-Gantenbein C, Marketos N, Chrousos GP, Papassotiriou I. Biomarkers of diabetic nephropathy: A 2017 update. Crit Rev Clin Lab Sci. 2017;54:326–42.PubMed

37.

Kolset SO, Reinholt FP, Jenssen T. Diabetic nephropathy and extracellular matrix. J Histochem Cytochem. 2012;60:976–86.PubMedPubMedCentral

38.

Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol. 2007;18:539–50.PubMed

39.

King GL, Loeken MR. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol. 2004;122:333–8.PubMed

40.

Suryavanshi SV, Kulkarni YA. NF-κβ: a potential target in the management of vascular complications of diabetes. Front Pharmacol. 2017;8:798. https://doi.org/10.3389/fphar.2017.00798.CrossRefPubMedPubMedCentral

41.

Ahmed S, Mundhe N, Borgohain M, Chowdhury L, Kwatra M, Bolshette N, et al. Diosmin modulates the NF-kB signal transduction pathways and downregulation of various oxidative stress markers in alloxan-induced diabetic nephropathy. Inflammation. 2016;39:1783–97.PubMed

42.

Sun L, Kanwar YS. Relevance of TNF-α in the context of other inflammatory cytokines in the progression of diabetic nephropathy. Kidney Int. 2015;88:662–5.PubMedPubMedCentral

43.

Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7:327–40.PubMed

44.

Salti T, Khazim K, Haddad R, Campisi-Pinto S, Bar-Sela G, Cohen I. Glucose induces IL-1α-dependent inflammation and extracellular matrix proteins expression and deposition in renal tubular epithelial cells in diabetic kidney disease. Front Immunol. 2020;11:1270. https://doi.org/10.3389/fimmu.2020.01270.CrossRefPubMedPubMedCentral

45.

Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Disc. 2012;11:633–52.

46.

Anders HJ. Of inflammasomes and alarmins: IL-1β and IL-1α in kidney disease. J Am Soc Nephrol. 2016;27:2564–75.PubMedPubMedCentral

47.

Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol Dial Transplant. 2007;22:827–32.PubMed

48.

Lei Y, Devarapu SK, Motrapu M, Cohen CD, Lindenmeyer MT, Moll S, Kumar SV, Anders HJ. Interleukin-1β inhibition for chronic kidney disease in obese mice with type 2 diabetes. Front Immunol. 2019;10:1223. https://doi.org/10.3389/fimmu.2019.01223.CrossRefPubMedPubMedCentral

49.

Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF. Inflammatory cytokines in diabetic nephropathy. J Diabetes Res. 2015. https://doi.org/10.1155/2015/948417.CrossRefPubMedPubMedCentral

50.

Zabad OM, Samra YA, Eissa LA. P-Coumaric acid alleviates experimental diabetic nephropathy through modulation of Toll like receptor-4 in rats. Life Sci. 2019. https://doi.org/10.1016/j.lfs.2019.116965.CrossRefPubMed

51.

Zhou B, Li Q, Wang J, Chen P, Jiang S. Ellagic acid attenuates streptozocin induced diabetic nephropathy via the regulation of oxidative stress and inflammatory signaling. Food Chem Toxicol. 2019;123:16–27.PubMed

52.

Zeng LF, Xiao Y, Sun L. A glimpse of the mechanisms related to renal fibrosis in diabetic nephropathy. Adv Exp Med Biol. 2019;1165:49–79.PubMed

53.

Hu C, Sun L, Xiao L, Han Y, Fu X, Xiong X, et al. Insights into the mechanisms involved in the expression and regulation of extracellular matrix proteins in diabetic nephropathy. Curr Med Chem. 2015;22:2858–70.PubMedPubMedCentral

54.

Lee HB, Yu MR, Yang Y, Jiang Z, Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol. 2003;14:241-5.

55.

Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol. 2003;23:532–43.PubMed

56.

Farris AB, Alpers CE. What is the best way to measure renal fibrosis? A pathologist’s perspective. Kidney Int Suppl. 2014;4:9–15.

Title: Nephroprotective effect of Vanillic acid in STZ-induced diabetic rats
Authors: Savita Kumari
Anjoo Kamboj
Manish Wanjari
Anil Kumar Sharma
Publication date: 01-06-2021
Publisher: Springer International Publishing
Keywords: Glimepiride
Insulins
Diabetic Nephropathy
Hyperglycemia
Albuminuria
Insulins
Published in: Journal of Diabetes & Metabolic Disorders / Issue 1/2021
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1007/s40200-021-00782-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Nephroprotective effect of Vanillic acid in STZ-induced diabetic rats

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Distress and depression among patients with diabetes mellitus: prevalence and associated factors: a cross‐sectional study

Vitamin D Receptor gene polymorphisms and susceptibility to type 2 diabetes: evidence from a meta-regression and meta-analysis based on 47 studies

Irrational beliefs trigger depression and anxiety symptoms, and associated with increased inflammation and oxidative stress markers in the 10-year diabetes mellitus risk: the ATTICA epidemiological study

Analysis of genetic selection at insulin receptor substrate-2 gene loci

Value-based eating habits; exploring religio-cultural nutritional behavior norms

Diabetic foot care course: a quasi-experimental study on E-learning versus interactive workshop

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page